Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model.

Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model.

An estimated 10 million people developed tuberculosis (TB) disease in 2019 which underscores the need for a vaccine that prevents disease and reduces transmission. The aim of our current studies is to characterize and test a prophylactic tuberculosis vaccine comprised of ID93, a polyprotein fusion a...

Full description

Bibliographic Details
Main Authors: Susan L Baldwin, Valerie A Reese, Sasha E Larsen, Elyse Beebe, Jeff Guderian, Mark T Orr, Christopher B Fox, Steven G Reed, Rhea N Coler
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0247990

Internet

https://doi.org/10.1371/journal.pone.0247990

Similar Items